Advancements in CGTs for cancer and other high-prevalence conditions are set to transform modern medicine. However, scientific development is outpacing our manufacturing ability to produce these therapies at required scales to reach tens of thousands, let alone millions of eligible patients a year. Current global production (<11,000 therapies/year in 2023) is critically insufficient to meet this growing demand. Furthermore, high treatment costs (~£300k-£3M) due to labour-intensive manufacturing processes are unsustainable to ensure affordable and accessible treatments. In response, we developed _Constellation_, a ground-breaking, fully-automated, AI-ready and robotically-mediated manufacturing platform for scalable, high-throughput, cost-effective and sustainable cell therapy manufacturing. _Constellation_ robotically mediates parallelised automation of manufacturing operations, whilst flexibly adapting to therapy developers' processes to enable rapid throughput scaling to 10,000s and onwards to 100,000s therapies/year without process redevelopment delays and costs. We are partnered with Cell and Gene Therapy Catapult (CGTC) to deploy _Constellation_ in their first-in-the-world, CGT-specific Digital and Automation Testbeds, serving as real-world test environments for accelerated development, testing and adoption of next-generation automation and digital technologies. This project builds on this first deployment and focuses on developing key functional improvements to expand _Constellation's_ capabilities and validating these through proof-of-concept studies using biological material. Through our partnership with CGTC, _Constellation_ will remain in CGTC's Testbeds long-term, accessible to therapy developers for de-risked testing and adoption. Project outcomes will also greatly de-risk and contribute to R&D for future _Constellation_ Versions. This project brings innovation towards cell therapy manufacturing to make more of these transformative treatments affordable and accessible at a time when manufacturing output needs to urgently increase. Significant long-term economical/societal impacts are expected from project outcomes that will boost the UK CGT's market growth and competitiveness globally, promoting world-leading biomanufacturing, robotics and AI innovation as per the UK Government's Life Sciences Vision.